Latest News for: ocular

Edit

Eye Drop Shop Announces Exclusive Canadian Partnership with Rinsada--the Breakthrough Ocular Irrigation Technology

Canada Newswire 17 Dec 2025
The Breakthrough Ocular Surface Irrigation Technology is now available in Canada ... with Rinsada , the revolutionary single-use ocular surface irrigation device transforming in-clinic dry eye care.
Edit

PainReform Confirms the Ability of Its LayerBio Drop-Less Sustained-Release Ocular Platform to Accommodate Multiple Drug Entities

Nasdaq Globe Newswire 10 Dec 2025
R&D assessment shows the platform can incorporate different drug entities onto ...
Edit

PainReform Confirms the Ability of Its LayerBio Drop-Less Sustained-Release Ocular Platform to

Hastings Tribune 10 Dec 2025
... drop-less, sustained-release ocular drug-delivery platform.
Edit

PainReform Confirms the Ability of Its LayerBio Drop-Less Sustained-Release Ocular Platform to Accommodate Multiple Drug Entities (Form 6-K) (PainReform Ltd)

Public Technologies 10 Dec 2025
Ocular Platform to Accommodate Multiple Drug Entities ... PRFX) today announced that its pharmaceutical division has completed an R&D assessment of LayerBio's proprietary drop-less, sustained-release ocular drug-delivery platform.
Edit

Ocular Therapeutix™ Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI™ in Wet AMD

Nasdaq Globe Newswire 08 Dec 2025
Ocular intends to submit AXPAXLI New Drug Application (NDA) for wet AMD shortly after year one data from SOL-1, if positive ... .
Edit

Ocular Inflammation and Pain Market & Epidemiology Outlook 2025-2034 Featuring Analysis of DEXTENZA, BYQLOVI and ...

Business Wire 08 Dec 2025
DUBLIN--(BUSINESS WIRE)--The "Ocular Inflammation and Pain - Market Insights, Epidemiology, and ...
Edit

Gatchalian runs ocular inspection of bicameral meeting venue

Manila Standard 07 Dec 2025
Senate finance chairman ...
Edit

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nasdaq Globe Newswire 05 Dec 2025
... Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Edit

Current Report (Form 8-K) (Ocular Therapeutix Inc)

Public Technologies 05 Dec 2025
). UNITED STATES. SECURITIES AND EXCHANGE COMMISSION. WASHINGTON, D.C. 20549. FORM 8-K ... OCULAR THERAPEUTIX, INC ... ¨ ... This Current Report on Form 8-K contains forward-looking statements of Ocular Therapeutix, Inc ... OCULAR THERAPEUTIX, INC ... Ocular Therapeutix Inc.
Edit

Formosa Pharmaceuticals Announces Licensing Agreement with Rxilient, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery

PR Newswire 03 Dec 2025
The licensing territory is estimated to have over 1 million ocular surgeries annually with anticipated YOY growth ... ocular surgery," said Erick Co, President and CEO of Formosa Pharmaceuticals.
Edit

PainReform Commences Development for OcuRing™-K Phase II Trial, LayerBio’s Drop-Less Sustained-Release Ocular Therapy

Nasdaq Globe Newswire 02 Dec 2025
Development plan positions OcuRing™-K for ...
Edit

PainReform Commences Development for OcuRing™-K Phase II Trial, LayerBio’s Drop-Less Sustained-Release Ocular Therapy (Form 6-K) (PainReform Ltd)

Public Technologies 02 Dec 2025
LayerBio's Drop-Less Sustained-Release Ocular Therapy ... By removing the need for patient-administered drops, OcuRing-K also reduces contamination risks, such as inadvertent contact between dropper bottles and ocular tissues.
Edit

Statement of Changes in Beneficial Ownership (Form 4) (Ocular Therapeutix Inc)

Public Technologies 26 Nov 2025
) FORM 4 ... Form 4 or Form 5 obligations may continue ... 2 ... OCULAR THERAPEUTIX, INC [OCUL] 5 ... C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE 3 ... C/O OCULAR THERAPEUTIX, INC ... (1) Represents shares of common stock of Ocular Therapeutix, Inc ... Ocular Therapeutix Inc.
Edit

Ocular Therapeutix™ Announces First Patient Randomized in HELIOS-3 Phase 3 Registrational Program for AXPAXLI™ in NPDR

Nasdaq Globe Newswire 24 Nov 2025
First patient randomized into HELIOS-3, which along with HELIOS-2 form the basis of AXPAXLI’s registrational program in non-proliferative diabetic retinopathy (NPDR) ... .
Edit

Notice of Proposed Sale of Securities (Form 144) (Ocular Therapeutix Inc)

Public Technologies 24 Nov 2025
). The text version of this document is not available ... Ocular Therapeutix Inc.

Article Search

tools
×
×
×
×